TICKERNERD
Menu
ELOXELOXHealthcare · Biotechnology

ELOX Stock Forecast: Eloxx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$17

The 4 Wall Street analysts covering Eloxx Pharmaceuticals, Inc. hold a median 12-month price target of $39 — +123.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$60.0M
Ticker Nerd rank
12 / 100
Median analyst target
$39
Analysts covering
4
Revenue$0.0
Operating income−$4.5M
Net income−$4.5M
Free cash flow−$4.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

ELOX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eloxx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Size
79
Volatility
50
Revisions
34
Issuance
22
Value
12
Growth
8
Accruals
8
Quality
4

Momentum (87): The shares have been drifting up relative to others.

Quality (4): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELOX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELOX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $32Median $39High $43

The green dot is the last close — the median target sits +123.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
18 Sept 2026Leerink PartnersInitiatesOutperform$32
24 Aug 2026GuggenheimReiteratesBuy$43
20 Aug 2026LUCID CAPITAL MARKETSInitiatesBuy$38
22 July 2026LifeSci CapitalInitiatesOutperform—
22 July 2026LifeSci CapitalInitiatesOutperform$40
20 July 2026GuggenheimInitiatesBuy—
20 July 2026GuggenheimInitiatesBuy$43
11 July 2023OppenheimerMaintainsOutperform$50 → $55
11 July 2023OppenheimerMaintainsOutperform—
6 Apr 2023OppenheimerReiteratesOutperform—
23 May 2022Piper SandlerMaintainsOverweight$4.00 → $1.50
9 May 2022HC Wainwright & Co.MaintainsNeutral$1.00 → $0.50
17 Dec 2021OppenheimerInitiatesOutperform—
18 Nov 2021HC Wainwright & Co.MaintainsNeutral$2.00 → $1.00
11 Nov 2021HC Wainwright & Co.MaintainsNeutral$3.00 → $2.00
30 June 2021MizuhoInitiatesBuy—
27 May 2021B. Riley SecuritiesInitiatesBuy—
11 June 2020CitigroupDowngradeNeutral$11 → $4.00
8 May 2020Janney CapitalMaintainsBuy—
8 May 2020Janney Montgomery ScottMaintainsBuy$13 → $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELOX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ELOX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Eloxx Pharmaceuticals, Inc. (ELOX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.0×

Cheaper than 66% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
−3.2×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
50.3%

Higher than 93% of US stocks

Return on assets
−113.8%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eloxx Pharmaceuticals, Inc. (ELOX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eloxx Pharmaceuticals, Inc. has a market value of $60.0M and an enterprise value of $20.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.9M.

  • Diluted earnings per share, trailing twelve months: $−11.94.

  • Free cash flow in the twelve months to 30 June 2026: −$10.8M.

  • Shares outstanding: 3.4M.

  • Trailing P/E: 5.0×; forward P/E: −24.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Eloxx Pharmaceuticals, Inc. employs 10 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

ELOX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELOXEloxx Pharmaceuticals, Inc.$60.0M
12
TENXTenax Therapeutics, Inc.$71.1M
20
PLRXPliant Therapeutics, Inc.$68.7M
67
RNTXRein Therapeutics, Inc.$68.4M
37
APLMApollomics, Inc.$68.3M
18
CSBRChampions Oncology, Inc.$73.1M
28
KLRSKalaris Therapeutics, Inc.$67.1M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eloxx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELOX news & analysis

Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

PRNewsWire · 11 Sept 2026positive

Eloxx Pharmaceuticals announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial of exaluren for nonsense mutation Alport syndrome. Topline data from the 16-week placebo-controlled portion are expected mid-2027, with a final readout expected by the end of 2027.

Why it matters — A watcher would care because dosing initiation moves the company's lead kidney-disease candidate forward in clinical development and establishes a timeline for key data readouts.

Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 12 Aug 2026positive

Eloxx Pharmaceuticals reported second quarter 2026 financial results and a business update, noting completion of an underwritten public offering with gross proceeds of $66.0 million, uplisting to the Nasdaq Capital Market, and European Commission orphan designation for exaluren in ADPKD. The company reported $62.0 million in cash as of June 30, 2026, expected to fund operations through data readouts, with a Phase 2b trial of exaluren in nonsense mutation Alport syndrome expected to begin in Q3 2026.

Why it matters — The strengthened balance sheet and planned trial initiation provide funding visibility through key data readouts for both Alport syndrome and ADPKD, the company's primary programs.

FAQ

Frequently asked questions about ELOX stock

What is the ELOX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Eloxx Pharmaceuticals, Inc. have a median 12-month price target of $39, with estimates ranging from $32 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELOX stock a buy right now?

Of the 4 analysts covering Eloxx Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eloxx Pharmaceuticals, Inc. 12 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELOX?

As at 19 Sept 2026, Eloxx Pharmaceuticals, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will ELOX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +123.5% from the last close, and Ticker Nerd's factor model ranks Eloxx Pharmaceuticals, Inc. 12 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELOX stock forecast for 2030?

No analyst covering Eloxx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELOX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $43 over the next 12 months.

What does Eloxx Pharmaceuticals, Inc. do?

Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations.

What is the latest news on ELOX?

The most recent item we track (PRNewsWire, 11 Sept 2026): "Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome". Eloxx Pharmaceuticals announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial of exaluren for nonsense mutation Alport syndrome. Topline data from the 16-week placebo-controlled portion are expected mid-2027, with a final readout expected by the end of 2027.

Company

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions. Eloxx also has a licensed program, ZKN-013, being advanced for rare dermatological diseases associated with nonsense mutations. Headquartered in Arlington, Massachusetts, Eloxx Pharmaceuticals operates in the biotechnology sector and serves a specialized niche in precision therapies for rare and ultra-rare disorders.

CEO Mr. Sumit Aggarwal M.B.A. · 10 employees · United States · https://www.eloxxpharma.com